$XTALPI(02228.HK) Thanks, boss. It's really rallying now 👍
Overview
XTALPI (2228)
XtalPi Holdings Limited operates as a research platform company in Mainland China, the United States, and internationally. The company offers XmartChem, an inte...
- Open
- 5.850
- High
- 5.850
- Low
- 5.430
- Prev. Close
- 5.870
- Volume
- 57.60M
- Turnover
- 318.76M
- Avg Price
- 5.534
- Bid/Ask Ratio
- 55.88%
- Amplitude
- 7.16%
- 52wk High
- 14.280
- Volume Ratio
- 1.12
- Turnover Ratio
- 1.34%
- 52wk Low
- 5.430
- HK Mkt Cap
- 23.74B
- Market CapHKD
- 23.74B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.0565
- EPSDynamic
- -0.135
- EPSStatic
- --
- BVPS
- 2.41
- P/B
- 2.29
- HK Shares
- 4.30B
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 4.30B
- Min lot size
- 1,000
- Currency
- HKD
XTALPI Analyst Rating
View moreForecast & Rating
Sep 16, 2026- Strong buy62.50%
- Buy12.50%
- Hold25.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 5
- Buy
- 1
- Hold
- 2
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
XtalPi fell 5.7% to HK$5.535 in a spike-and-fade session that printed a fresh 52-week low of HK$5.43 at 10:48 BJ, with the HK$5.85 open marking the day's high and turnover reaching HK$313.4 million at a 1.32% turnover rate. The drag is fundamental: Q2 2026 revenue of HK$227.3 million fell 19.76% year on year, the operating loss reached HK$225.1 million, net loss was HK$145.5 million on a -64% net margin, with EPS of -HK$0.0356 and a PE of -97.9x. The stock has repeatedly probed 52-week lows since the share buyback was cancelled, and a roughly HK$25 million chairman purchase at range lows failed to stop the slide. It is down 44.6% year to date, 61.2% below the 52-week high of HK$14.28, and trades under the MA20 of HK$6.09 and MA60 of HK$6.94, only 1.9% above the 52-week low. Though Q2 revenue edged above Q1's HK$223.7 million and the net loss was broadly flat versus HK$143.2 million.
- Nov, 12
XtalPi (2228.HK) opened at HK$6.34 and faded through the session, touching HK$5.935 in the afternoon before closing at HK$6.04, down 5.1% from HK$6.365, on 48.5 million shares and HK$299 million turnover (1.13% turnover rate); the intraday high of HK$6.365 was set at 11:01 in the morning session. No fresh catalyst emerged, and the stock is still absorbing the October cancellation of its share buyback; it hit a 52-week low of HK$5.60 on 22 October and now trades just 7.86% above that level but 57.7% below its 13 January high of HK$14.28, down 39.54% year-to-date and below both MA20 (HK$6.109) and MA60 (HK$7.009). Fundamentals offered little support: Q2 2026 revenue fell 19.76% yoy to HK$227.3 million while the net loss widened 420.7% to HK$145.5 million, a -64% net margin and EPS of -HK$0.0356, against a PB of 2.50 and market capitalisation of HK$25.95 billion. A HK$25 million chairman purchase has not reversed the drift, though the close came off the HK$5.935 low rather than at the session bottom.
- Nov, 9
AI-drug-discovery news lifted XTALPI (2228.HK) to a 6.450 HKD gap-up open, but the stock peaked at 6.425 HKD by 09:42 BJ and then faded through the afternoon to 6.210 HKD at 15:56, closing at 6.250 HKD, up 2.04% on 36.65 million shares and 231.6 million HKD of turnover (0.85% turnover rate) — a clear pop-and-fade. The day's company flow centred on an AI-driven drug discovery collaboration with Laboratoires Pierre Fabre and a memorandum of understanding with Singapore's A*STAR. The bounce still leaves the shares down 37.44% year-to-date, 56.23% below the 14.28 HKD 52-week high set on 13 January, though 11.6% above the 5.60 HKD low of 22 October; price sits above the 6.147 HKD MA20 but below the 7.083 HKD MA60. While the 22 October cancellation of 4.882 million repurchased shares came shortly before that 52-week low, the stock now trades on a negative PE of -110.56 and 2.59x PB, and QuantumPharm added 1 million shares at 5.9051 HKD.
- Nov, 6
Hong Kong biotech names pulled back and the HSI opened 392 points lower, and XtalPi traced a spike-and-fade session, dipping to HK$6.06 at 09:42 BJ before spiking to HK$6.22 by 09:59 and then drifting sideways through the afternoon to close at HK$6.12 on 34.7 million shares and HK$213 million of turnover. The operating picture remains weak: Q2 2026 revenue of HK$227.3 million fell 19.8% year on year, the net loss widened to HK$145.5 million, net margin stood at -64.0% and EPS at -HK$0.0356. The stock is down 38.6% year to date and 57.1% below its January 13 52-week high of HK$14.28, and although it has rebounded 9.5% from the October 22 low of HK$5.60, it still trades under its MA20 of HK$6.19 and MA60 of HK$7.12. Though a memorandum of understanding with Singapore's A*STAR plus chairman and QuantumPharm purchases near HK$5.9 offer a counterpoint.
- Nov, 5
XtalPi Holdings rose 4.0% to HK$6.36 in a low-open, high-close session, dipping to HK$6.14 at the open before spiking to HK$6.425 at 11:05 BJ and consolidating through the afternoon on 66.54 million shares worth about HK$421 million, a 1.55% turnover, while the Hang Seng gained 0.43% at midday with biotech leading. Sentiment was supported by a memorandum of understanding with Singapore's Agency for Science, Technology and Research, chairman Wen Shuhao's cumulative purchase of 3.793 million shares, and QuantumPharm's 1 million-share increase at HK$5.9051 each, alongside Guosheng Securities' positive view on the AI-empowered innovation value chain. Fundamentals remain weak though: Q2 2026 revenue fell 19.76% year on year to HK$227.3 million, with a net loss of HK$145.5 million, a -63.99% net margin and EPS of -HK$0.0356; the stock is down 36.34% year to date and 55.46% below its 52-week high of HK$14.28, above the MA20 of HK$6.236 but below the MA60 of HK$7.15, with PB at 2.64 and PE negative.
News
Market Movers · XTALPI drops 5% to 52-week low
Weekly Review · Weekly Recap | XTALPI -6.16%, consensus target above spot
Market Movers · XTALPI falls nearly 6% in Hong Kong trading
Weekly Review · Weekly Recap | XTALPI +1.83%, consensus target well above spot
HK Stock Market Update · XtalPi Holdings edges up 1% in Hong Kong trading
Weekly Review · Weekly Recap | XTALPI +2.11%, chairman buying at a range low
